zonisamide has been researched along with Canine Diseases in 11 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on these results, zonisamide monotherapy is effective in some dogs with idiopathic epilepsy." | 9.16 | Zonisamide monotherapy for idiopathic epilepsy in dogs. ( Ahn, JO; Chae, JS; Chung, JY; Hwang, CY; Kim, TH; Lee, SY; Seo, KW; Youn, HY, 2012) |
| "Investigation of the efficacy of zonisamide as an add-on therapy in dogs with refractory epilepsy." | 9.12 | Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. ( Rambeck, B; Tipold, A; von Klopmann, T, 2007) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 8.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "A 3-year-old neutered male golden retriever administered zonisamide for the treatment of seizures showed lethargy and had normal anion gap metabolic acidosis with hypokalaemia, hyperchloremia, and alkaline urine." | 8.12 | Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy. ( Akashi, N; Hata, A; Itoi, T; Kanda, T; Kutara, K; Miyama, TS; Shimizu, Y; Sugimoto, K, 2022) |
| "This report describes a dog that developed erythema multiforme in temporal association with administration of the sulphonamide-based anticonvulsant drug zonisamide." | 7.81 | Erythema multiforme associated with zonisamide in a dog. ( Ackermann, AL; Frank, LA; May, ER; McEntee, MF, 2015) |
| "A 9-year old female spayed Rottweiler was diagnosed with cryptogenic epilepsy and started on zonisamide monotherapy (8." | 7.77 | Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy. ( Muñana, KR; Olby, NJ; Schwartz, M, 2011) |
| "Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods." | 7.30 | Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. ( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023) |
| "Based on these results, zonisamide monotherapy is effective in some dogs with idiopathic epilepsy." | 5.16 | Zonisamide monotherapy for idiopathic epilepsy in dogs. ( Ahn, JO; Chae, JS; Chung, JY; Hwang, CY; Kim, TH; Lee, SY; Seo, KW; Youn, HY, 2012) |
| "Investigation of the efficacy of zonisamide as an add-on therapy in dogs with refractory epilepsy." | 5.12 | Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. ( Rambeck, B; Tipold, A; von Klopmann, T, 2007) |
| "To investigate caregivers' assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy." | 4.31 | Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy. ( Gristina, BR; Muñana, KR; Nettifee, JA; Waldron, RJ, 2023) |
| "A 3-year-old neutered male golden retriever administered zonisamide for the treatment of seizures showed lethargy and had normal anion gap metabolic acidosis with hypokalaemia, hyperchloremia, and alkaline urine." | 4.12 | Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy. ( Akashi, N; Hata, A; Itoi, T; Kanda, T; Kutara, K; Miyama, TS; Shimizu, Y; Sugimoto, K, 2022) |
| "This report describes a dog that developed erythema multiforme in temporal association with administration of the sulphonamide-based anticonvulsant drug zonisamide." | 3.81 | Erythema multiforme associated with zonisamide in a dog. ( Ackermann, AL; Frank, LA; May, ER; McEntee, MF, 2015) |
| "A 9-year old female spayed Rottweiler was diagnosed with cryptogenic epilepsy and started on zonisamide monotherapy (8." | 3.77 | Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy. ( Muñana, KR; Olby, NJ; Schwartz, M, 2011) |
| "Seizure frequency (seizures/month; sz/m), blood tests including concentrations of ZNS and β-hydroxybutyric acid, and owner's visual analogue scale score were collected from all dogs for both treatment periods." | 3.30 | Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. ( Hasegawa, D; Nakatsuka, K; Zanghi, B, 2023) |
| " A population pharmacokinetic approach and nonlinear mixed effects modeling were used to analyze the data." | 1.48 | Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide. ( Muñana, KR; Nettifee, JA; Otamendi, AJ; Papich, MG, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, TK | 1 |
| Cameron, S | 1 |
| Trepanier, LA | 1 |
| Itoi, T | 1 |
| Akashi, N | 1 |
| Shimizu, Y | 1 |
| Sugimoto, K | 1 |
| Hata, A | 1 |
| Kutara, K | 1 |
| Miyama, TS | 1 |
| Kanda, T | 1 |
| Gristina, BR | 1 |
| Waldron, RJ | 1 |
| Nettifee, JA | 2 |
| Muñana, KR | 3 |
| Nakatsuka, K | 1 |
| Zanghi, B | 1 |
| Hasegawa, D | 1 |
| Takami, Y | 1 |
| Izawa, T | 1 |
| Tanaka, M | 1 |
| Hatoya, S | 1 |
| Nabetani, T | 1 |
| Yamate, J | 1 |
| Kuwamura, M | 1 |
| Tanaka, N | 1 |
| Kanei, T | 1 |
| Iwata, M | 1 |
| Kawabe, M | 1 |
| Kamishina, H | 1 |
| Murakami, M | 1 |
| Sakai, H | 1 |
| Maeda, S | 1 |
| Otamendi, AJ | 1 |
| Papich, MG | 1 |
| Ackermann, AL | 1 |
| Frank, LA | 1 |
| McEntee, MF | 1 |
| May, ER | 1 |
| Schwartz, M | 1 |
| Olby, NJ | 1 |
| Chung, JY | 1 |
| Hwang, CY | 1 |
| Chae, JS | 1 |
| Ahn, JO | 1 |
| Kim, TH | 1 |
| Seo, KW | 1 |
| Lee, SY | 1 |
| Youn, HY | 1 |
| von Klopmann, T | 1 |
| Rambeck, B | 1 |
| Tipold, A | 1 |
3 trials available for zonisamide and Canine Diseases
| Article | Year |
|---|---|
Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study.
Topics: Animals; Diet; Dog Diseases; Dogs; Epilepsy; Prospective Studies; Seizures; Triglycerides; Zonisamid | 2023 |
Zonisamide monotherapy for idiopathic epilepsy in dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Isoxazoles; Zonisamide | 2012 |
Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs.
Topics: Administration, Oral; Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Isoxazoles; Prospectiv | 2007 |
8 other studies available for zonisamide and Canine Diseases
| Article | Year |
|---|---|
Incidence of hepatopathies in dogs administered zonisamide orally: A retrospective study of 384 cases.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Incidence; Liver Diseases; Retrospective Studies; Zoni | 2022 |
Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy.
Topics: Acidosis, Renal Tubular; Animals; Bicarbonates; Dog Diseases; Dogs; Epilepsy; Lethargy; Male; Zonisa | 2022 |
Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy.
Topics: Animals; Anticonvulsants; Caregivers; Dog Diseases; Dogs; Epilepsy; Humans; Levetiracetam; Phenobarb | 2023 |
Hepatocellular necrosis with prominent regenerative reactions in a zonisamide administrated dog.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Liver; Liver R | 2020 |
Detection of granzyme B in CD3-positive cells infiltrated in lesional skin of a dog with erythema multiforme associated with zonisamide.
Topics: Animals; Dog Diseases; Dogs; Erythema Multiforme; Granzymes; Zonisamide | 2021 |
Population pharmacokinetics of extended-release levetiracetam in epileptic dogs when administered alone, with phenobarbital or zonisamide.
Topics: Animals; Anticonvulsants; Delayed-Action Preparations; Dog Diseases; Dogs; Drug Interactions; Epilep | 2018 |
Erythema multiforme associated with zonisamide in a dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Erythema Multiforme; Isoxazoles; Male; Skin; | 2015 |
Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Dog Diseases; Dogs; Epilepsy; Fema | 2011 |